AAAAAA

   
Results: 1-10 |
Results: 10
Plasma concentration monitoring of busulfan - Does it improve clinical outcome?
Authors: McCune, JS Gibbs, JP Slattery, JT
Citation: Js. Mccune et al., Plasma concentration monitoring of busulfan - Does it improve clinical outcome?, CLIN PHARMA, 39(2), 2000, pp. 155-165
An evaluation of engraftment, toxicity and busulfan concentration in children receiving bone marrow transplantation for leukemia or genetic disease
Authors: Bolinger, AM Zangwill, AB Slattery, JT Glidden, D DeSantes, K Heyn, L Risler, LJ Bostrom, B Cowan, MJ
Citation: Am. Bolinger et al., An evaluation of engraftment, toxicity and busulfan concentration in children receiving bone marrow transplantation for leukemia or genetic disease, BONE MAR TR, 25(9), 2000, pp. 925-930
Busulfan clearance in renal failure and hemodialysis
Authors: Ullery, LL Gibbs, JP Ames, GW Senecal, FM Slattery, JT
Citation: Ll. Ullery et al., Busulfan clearance in renal failure and hemodialysis, BONE MAR TR, 25(2), 2000, pp. 201-203
Ethanol and production of the hepatotoxic metabolite of acetaminophen in healthy adults
Authors: Thummel, KE Slattery, JT Ro, H Chien, JY Nelson, SD Lown, KE Watkins, PB
Citation: Ke. Thummel et al., Ethanol and production of the hepatotoxic metabolite of acetaminophen in healthy adults, CLIN PHARM, 67(6), 2000, pp. 591-599
Contribution of CYP2E1 and CYP3A to acetaminophen reactive metabolite formation
Authors: Manyike, PT Kharasch, ED Kalhorn, TF Slattery, JT
Citation: Pt. Manyike et al., Contribution of CYP2E1 and CYP3A to acetaminophen reactive metabolite formation, CLIN PHARM, 67(3), 2000, pp. 275-282
Allogeneic and syngeneic marrow transplantation for myelodysplastic syndrome in patients 55 to 66 years of age
Authors: Deeg, HJ Shulman, HM Anderson, JE Bryant, EM Gooley, TA Slattery, JT Anasetti, C Fefer, A Storb, R Appelbaum, FR
Citation: Hj. Deeg et al., Allogeneic and syngeneic marrow transplantation for myelodysplastic syndrome in patients 55 to 66 years of age, BLOOD, 95(4), 2000, pp. 1188-1194
Analysis of cyclophosphamide and five metabolites from human plasma using liquid chromatography-mass spectrometry and gas chromatography-nitrogen-phosphorus detection
Authors: Kalhorn, TF Ren, S Howald, WN Lawrence, RF Slattery, JT
Citation: Tf. Kalhorn et al., Analysis of cyclophosphamide and five metabolites from human plasma using liquid chromatography-mass spectrometry and gas chromatography-nitrogen-phosphorus detection, J CHROMAT B, 732(2), 1999, pp. 287-298
Up-regulation of glutathione S-transferase activity in enterocytes of young children
Authors: Gibbs, JP Liacouras, CA Baldassano, RN Slattery, JT
Citation: Jp. Gibbs et al., Up-regulation of glutathione S-transferase activity in enterocytes of young children, DRUG META D, 27(12), 1999, pp. 1466-1469
Inhibition of human aldehyde dehydrogenase 1 by the 4-hydroxycyclophosphamide degradation product acrolein
Authors: Ren, S Kalhorn, TF Slattery, JT
Citation: S. Ren et al., Inhibition of human aldehyde dehydrogenase 1 by the 4-hydroxycyclophosphamide degradation product acrolein, DRUG META D, 27(1), 1999, pp. 133-137
The impact of obesity and disease on busulfan oral clearance in adults
Authors: Gibbs, JP Gooley, T Corneau, B Murray, G Stewart, P Appelbaum, FR Slattery, JT
Citation: Jp. Gibbs et al., The impact of obesity and disease on busulfan oral clearance in adults, BLOOD, 93(12), 1999, pp. 4436-4440
Risultati: 1-10 |